Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.
about
GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesityCyclic AMP dynamics in the pancreatic β-cellRap1 promotes multiple pancreatic islet cell functions and signals through mammalian target of rapamycin complex 1 to enhance proliferationSynergistic effect of cAMP and palmitate in promoting altered mitochondrial function and cell death in HepG2 cells.Nicotinamide ameliorates palmitate-induced ER stress in hepatocytes via cAMP/PKA/CREB pathway-dependent Sirt1 upregulationInhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes.cAMP mediators of pulsatile insulin secretion from glucose-stimulated single beta-cells.Repurposing cAMP-modulating medications to promote β-cell replication.HD047703, a New Promising Anti-Diabetic Drug Candidate: In Vivo Preclinical Studies.Chronic hyperglycemia downregulates GLP-1 receptor signaling in pancreatic β-cells via protein kinase AAltered expression of somatostatin receptors in pancreatic islets from NOD mice cultured at different glucose concentrations in vitro and in islets transplanted to diabetic NOD mice in vivo.A-kinase anchoring proteins take shape.GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.Emerging micro- and nanotechnology based synthetic approaches for insulin delivery.Optogenetic regulation of insulin secretion in pancreatic β-cells.
P2860
Q24653673-37A0E9A8-6970-4F2E-91A9-6D7539A0237EQ27008275-933BAABC-26FC-4FC5-9726-AA73234F12A2Q28567162-E74484F3-043D-4CEF-9843-DB0E897DD4EAQ33678599-16AC6167-5F1B-477D-B6D6-7AD9B2F3801FQ33731432-0E4F80C9-C7E3-4D57-A0FD-2DAFADBF68D0Q33844872-9FF9E3CF-A664-4A9A-8891-2341F0E73DDAQ34003897-2ECA7D96-2B59-4922-A580-A343F27BCAB2Q34265051-13F30A19-F527-46A0-A19B-A8584FB13BE4Q34360545-43967C45-5014-4D70-9FDC-B6F649FE63BBQ35163101-8B219AEF-71A8-41C0-A2CF-839BAB05F912Q35196943-88567962-E4F5-45AC-B36E-FE24FAB37705Q36463252-9DB3167B-F559-45A0-ADEC-5E77557BA05CQ38089183-594487BB-9C55-41E6-B006-78B83A9C8CC8Q38195730-02D09EAA-F994-452F-A566-538739C655BBQ41518152-91985671-E0A6-4CA9-9947-D18BE88A6197
P2860
Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Targeting beta-cell cyclic 3'5 ...... 2 diabetes mellitus. A review.
@ast
Targeting beta-cell cyclic 3'5 ...... 2 diabetes mellitus. A review.
@en
type
label
Targeting beta-cell cyclic 3'5 ...... 2 diabetes mellitus. A review.
@ast
Targeting beta-cell cyclic 3'5 ...... 2 diabetes mellitus. A review.
@en
prefLabel
Targeting beta-cell cyclic 3'5 ...... 2 diabetes mellitus. A review.
@ast
Targeting beta-cell cyclic 3'5 ...... 2 diabetes mellitus. A review.
@en
P2093
P2860
P356
P1476
Targeting beta-cell cyclic 3'5 ...... 2 diabetes mellitus. A review.
@en
P2093
Brian Furman
Finbarr O'Harte
Nigel Pyne
Peter Flatt
P2860
P304
P356
10.1211/0022357044805
P577
2004-12-01T00:00:00Z